Pharma BD Deal Intelligence
A win with a debt-funded footnote: BD's $24B purchase of Bard bolted vascular access, oncology, and urology franchises onto its portfolio, creating a combined company with roughly $16 billion in annualized revenue and durable category leadership across those lines.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Becton Dickinson buys CR Bard for $24 billion to form medical supply giant. Bard shareholders received $222.93 in cash and 0.5077 shares of Becton Dickinson…
Evercore IS analyst Vijay Kumar said the deal would make BD an indispensable partner to hospitals as changing industry dynamics drive customer consolidation
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Becton Dickinson acquired C.R. Bard for approximately $24 billion in cash and stock ($222.93 in cash and 0.5077 BD shares per Bard share). The combination created a healthcare leader with approximately $16 billion in annualized revenue.
$8.0B Global Vascular Access (2017)
BD acquired C.R. Bard for $24B in 2017. Leading vascular access, urology, peripheral intervention.
Bard's vascular access, hernia repair, peripheral intervention combined with BD's needles/syringes. BD now ~$20B revenue.
Becton Dickinson agrees to acquire C.R. Bard for $317/share in cash and stock ($24B total), creating a medtech leader with ~$16B annualized revenue across vascular access, surgery, and urology.
BD commences exchange offers and consent solicitations for C.R. Bard notes as part of deal financing structure.
U.S. FTC clears the acquisition contingent on BD divesting its soft tissue core needle biopsy line and Bard divesting its Aspira tunneled home drainage catheter line.
Ministry of Commerce of China provides the final regulatory approval needed, clearing the last jurisdiction for deal completion.
BD completes the $24B acquisition of C.R. Bard. Each Bard share converts to $222.93 cash plus 0.5077 BD shares, creating a combined medtech company with ~$16B revenue.
BD reports FY2018 revenue of $15.98B, up 32% year-over-year, reflecting the first full year of Bard contribution and validating the revenue synergy thesis.
BD-Bard is a textbook medtech deal: complementary portfolios (BD in injection/infusion, Bard in vascular/urology), manageable regulatory path, and immediate revenue accretion. The 32% revenue jump in FY2018 confirmed synergy capture. No major integration failures surfaced.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Becton, Dickinson and Company / C.R. Bard Inc. (this deal) | 2017 | $24.0B | 77 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Johnson & Johnson / Synthes Inc. | 2011 | $19.7B | 77 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |
| Danaher Corporation / GE Life Sciences Biopharma Business (now Cytiva) | 2019 | $21.4B | 76 |
| Roche Holding AG / Halozyme Therapeutics, Inc. | 2017 | $190M | 75 |